Recombinant protein drugs are significantly safer than small molecule drugs. Although the production conditions are harsh, the taking procedure is complicated and the price is expensive, it has an irreplaceable therapeutic effect on certain diseases, so it has a high approval rate. At the same time, the clinical trial period of recombinant protein drugs is shorter than that of small molecule drugs, and the patent protection is relatively extended, giving pharmaceutical companies a longer exclusive profit time. These characteristics have become an important driving force for the development of recombinant protein drugs.
Genetic engineering of recombinant protein drugs is one of the important development directions of new drug development. Today, although recombinant protein drugs only account for 7-8% of the global prescription drug market, they are developing very rapidly, with the top 10 "heavy bomb" drugs accounting for more than 60% of total sales.
In the next 5-10 years, China's biopharmaceutical field will still use recombinant protein as the mainstream, which is in line with the development trend of the world's biopharmaceutical field. China's recombinant protein drugs will still focus on tracking research and improved research and development. In the selection of research and development varieties, "heavy bomb" products will still be the main starting point for research, which is not entirely attributed to domestic biopharmaceutical companies. "Racing up", from a global perspective, the transformation of existing "blockbuster" protein drugs is a major development trend.
Another noteworthy aspect is the improvement of production capacity. Not only in China, the lack of production capacity in the biopharmaceutical industry worldwide has become a bottleneck for the development of recombinant drugs. Insufficient production capacity leads to increased production costs, which limits industrialization to a certain extent. To put it another way, an advantage in production capacity is a barrier. Recombinant protein refers to the protein produced by recombinant DNA technology. The earliest batch of biopharmaceutical companies mainly used genetic engineering technology to obtain protein. We call it "the use of genetic engineering processing technology to produce protein."
Hot Sale Products,High Quality Hot Sale Products,Hot Sale Products Details, CN
ZHEJIANG HUZOLI METAL PRODUCTS CO.,LTD , https://www.zlplasticfurniture.com